PRODUCTS

krrxyxSlxGl

krrxyxSlxGl (5225)

119066

An envelope esomeprazole purchase Ian Gordon, an analyst at Investec, said: “Frankly, from a purely financial perspective, we regard £50m as a source of relief! We were forecasting a decline from £7bn in quarter three 2012 to £6.8bn in quarter three 2013, so the outturn appears worse, with Barcap income ‘significantly below’ July-August 2012. In this context, underlying costs being ‘on track’ to meet an £18.5bn target offers little consolation.”

An envelope esomeprazole purchase Ian Gordon, an analyst at Investec, said: “Frankly, from a purely financial perspective, we regard £50m as a source of relief! We were forecasting a decline from £7bn in quarter three 2012 to £6.8bn in quarter three 2013, so the outturn appears worse, with Barcap income ‘significantly below’ July-August 2012. In this context, underlying costs being ‘on track’ to meet an £18.5bn target offers little consolation.”

VAT Relief available

£6.00 Excluding VAT

£7.20 Including VAT

Website maintained by CIUK